Bristol-Myers Squibb

Bristol-Myers Squibb's reported carbon emissions

Bristol-Myers Squibb (BMS), a pharmaceutical preparation manufacturer headquartered in the US, reported a total of approximately 2.01 billion kg CO2e in Scope 1, 2, and 3 emissions for the year 2024. This figure breaks down into approximately 206.73 million kg CO2e for Scope 1 emissions, with stationary combustion being the largest contributor. Scope 2 emissions, calculated on a market-based approach, were approximately 104.65 million kg CO2e. Scope 3 emissions constituted the largest portion, totalling approximately 1.70 billion kg CO2e, with purchased goods and services accounting for the majority of this. In 2023, BMS's total emissions were approximately 2.12 billion kg CO2e. Scope 1 emissions were approximately 208.53 million kg CO2e, Scope 2 emissions were approximately 158.45 million kg CO2e (market-based), and Scope 3 emissions were approximately 1.75 billion kg CO2e. BMS has set ambitious climate commitments, including a goal to achieve Net Zero emissions across its value chain by 2050. More specifically, the company aims for net neutrality in Scope 1 and Scope 2 greenhouse gas (GHG) emissions by 2040. Further demonstrating its commitment, BMS has pledged to reduce absolute Scope 1 and 2 GHG emissions by 54.6% by 2033, using 2022 as a base year. The company is also working towards reducing absolute Scope 3 GHG emissions by 90% by 2050 from a 2022 base year. In line with these goals, BMS aims to have 75% of its suppliers, by emissions, develop science-based targets by 2028, covering categories such as purchased goods and services, capital goods, and upstream transportation and distribution.